This study also provided evidence that bevacizumab or VEGFR-targeted therapy in prostate cancer is more efficacious if it is combined with targeted inhibition of the NRP2 effectors P-Rex1 and Rac1 [74]. Here, NRP2 is linked to Familial prostate cancer.